The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 15, 2025

Filed:

Nov. 29, 2022
Applicant:

Intrexon Actobiotics NV, Zwijnaarde, BE;

Inventors:

Pieter Rottiers, De Pinte, BE;

Lothar Steidler, Lokeren, BE;

Assignee:

INTREXON ACTOBIOTICS N.V., Zwijnaarde, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/74 (2006.01); A61K 35/744 (2015.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61P 3/10 (2006.01); C07K 14/54 (2006.01); C07K 14/62 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C12N 15/746 (2013.01); A61K 35/744 (2013.01); A61K 39/3955 (2013.01); A61P 3/10 (2018.01); C07K 14/5428 (2013.01); C07K 14/62 (2013.01); C07K 16/2809 (2013.01); C12N 15/74 (2013.01);
Abstract

The current disclosure provides microorganisms, such as lactic acid bacteria (e.g.,) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a T1D-specific antigen (e.g., a proinsulin) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbial strains are suitable for human therapy. The disclosure further provides compositions (e.g., pharmaceutical compositions) methods of using the microorganisms and compositions, e.g., for the treatment of type 1 diabetes (T1D), including those with residual beta-cell function, e.g., recent-onset T1D. The microorganism may be administered orally, delivers the microorganism into the gastrointestinal tract, where it is released and expresses the bioactive polypeptides. The methods of the present disclosure are particularly well suited for subjects possessing residual beta-cell function, e.g., for subjects with recent-onset T1D.


Find Patent Forward Citations

Loading…